Safety Study of Phage Therapy for Serious Infections in Adults

What this Trial Is About

Researchers are describing the side effects related to using bacteriophages to treat serious infections. This observational cohort study focuses on gathering information about these adverse events, as there is very little data currently available. The study is sponsored by Hospices Civils de Lyon and includes patients with severe infections treated with phage therapy, sometimes alongside surgery. Patients in the study receive phage injections to combat their infections. The study includes an additional biobanking component where blood samples are collected before and after phage treatment. These samples include blood, serum, and immune cells to explore if immune responses to phages contribute to any side effects. Participants provide data on any serious adverse events up to 12 months after phage injection. Blood samples are collected and stored for up to 6 months post-treatment to support immune response studies. The research team monitors and classifies adverse events to understand if they relate to surgery, antibiotics, or phages. Participants remain in the study to help gather detailed safety data over time.

Phage Safety Cohort Study